BUZZ - Hims & Hers shares rise on potential sales of certain unapproved peptide products
路透社2026/10/28 17:51October 28 - ** Hims & Hers Health (HIMS.N) shares rose 5% to $29.35 after the U.S. health authorities said they would temporarily allow (link) the sale of certain unapproved peptide products
** The telemedicine company HIMS stated that if regulations permit, the company plans to offer peptide products
** The interim policy covers six peptide substances, including the popular tissue repair compound BPC-157. Regulators are deciding on formally allowing its use in compounding medications
** Leerink analyst Michael Cherny indicated that this move, in theory, brings the market opportunity for these peptide drugs forward by at least several months
** However, he also cautioned: "This notice is still far from the 'green light' HIMS would need to fully capitalize on this opportunity"
** The stock is down 10.6% year to date
(To assist non-native English speakers, Reuters has automatically translated its report into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation. These are provided solely for the convenience of readers. Reuters accepts no responsibility for any damages or losses arising from use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Commodity cost headwinds increase to 2.5 billions USD, Ford Motor (F.US) sees core profit edge up 4% against the trend in Q3 and raises its annual guidance lower limit
Ford's Q3 adjusted EPS exceeded expectations by 20%, and the company raised the lower end of its full-year profit guidance to $10.5 billion; however, revenue slightly missed expectations, causing shares to fall nearly 2% after hours.
AI contract manufacturing and advanced packaging drive double inflection points, KLAC (KLAC.US) posts ten consecutive quarters of revenue growth, Q2 guidance exceeds expectations
KLA Corporation (KLAC.US) reported first-quarter revenue of $4.136 billions, surpassing expectations and marking ten consecutive quarters of growth. The company's guidance for the next quarter remains strong, with shares rising 3.2% after hours, as ongoing AI demand continues to drive momentum.
Crypto prices
More
